Table 1.

Monotherapy (single agent) activity of i.p. PR-104 using a q4d × 3 schedule (1.07 mmol/kg/dose) against human tumor xenografts in CD-1 nude mice

Tumors and size at treatment
Survival
Tumor growth inhibition
XenograftTissue originTumor volume, mean ± SD (mm3)Median life extension (days)Long-term controls*Log rank (P)SGD (%)Mann-Whitney test (P)
H460Lung218 ± 126351/12<0.001400<0.001
H1299Lung310 ± 6182/60.012400.527
HT29Colon296 ± 51390/60.0021920.004
SiHaCervix254 ± 33>773/60.0125310.009
C33ACervix252 ± 4550/70.056530.006
MiaPaCa-2Pancreas329 ± 65120/50.514810.151
Panc-01Pancreas165 ± 46210/8<0.00194<0.001
A2780Ovary254 ± 80261/15<0.001460<0.001
  • * Tumors nonpalpable or below end point size (mean diameter, 15 mm) at 100 d.

  • SGD (median tumor growth delay as a % of median time for controls to reach end point; see Materials and Methods).

  • Pooled analysis of two experiments.